UPDATE: Genomma Lab Will Proceed to Terminate Financing for Prestige Brands Deal
Genomma Lab Internacional, S.A.B. de C.V. ("Genomma") (BMV: LAB.B.) announced today that it has decided to no longer pursue the proposed acquisition of all of the outstanding shares of Prestige Brands Holdings, Inc. ("Prestige") (NYSE: PBH) common stock for $16.60 per share in cash. Since Genomma's initial proposal to Prestige on February 21, 2012, Genomma satisfied Prestige's conditions by: o Given Genomma's financial strength, it obtained the COMMITTED FINANCING of approximately US$2.2 BILLION, subject to customary conditions, to finance the transaction. These commitments were filed to the Securities and Exchange Commission ("SEC") and to the Comision Nacional Bancaria de Valores ("CNBV")
(c) 2013 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.